Abstracts tagged "juvenile idiopathic arthritis (JIA) and juvenile idiopathic arthritis-enthesitis (ERA)"

Abstract Number: 371 • 2017 ACR/ARHP Annual Meeting
Longer Term Outcomes of Chronic Relapsing Multifocal Osteomyelitis in a UK Tertiary Adolescent and Young Adult Rheumatology Centre
Kristina E.N. Clark¹, Francesca Josephs², Nicola Daly³, Claire Louise Murphy³ and Debajit Sen⁴, ¹Rheumatology, University college London Hospitals, London, United Kingdom, ²rhuematology, UCL, London, United Kingdom, ³Rheumatology, University College London Hospital, London, United Kingdom, ⁴Adolescent Rheumatology Department, University College London Hospital NHS Trust, London, United Kingdom
Background/Purpose: Chronic relapsing multifocal osteomyelitis (CRMO) is a rare autoinflammatory bone condition presenting primarily in children & adolescents. It characteristically affects the epiphysis & metaphysis…
Abstract Number: 2431 • 2015 ACR/ARHP Annual Meeting
Long-Term Safety of Adalimumab Treatment in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis and Enthesitis-Related Arthritis
Daniel Lovell¹, Nicolino Ruperto², Daniel J. Kingsbury¹, Rubén Burgos-Vargas², Tomoyuki Imagawa³, G Horneff², Pierre Quartier⁴, Steven Goodman¹, Andreas Reiff¹, Edward H. Giannini¹, Anabela Cardoso⁵, Jaclyn K. Anderson⁶, Nupun A. Varothai⁶, Jasmina Kalabic⁶ and Alberto Martini², ¹PRCSG, Cincinnati, OH, ²PRINTO, IRCCS G. Gaslini, Genova, Italy, ³Kanagawa Children’s Medical Center, Yokohama City, Japan, ⁴Hopital Necker-Enfants Malades, Paris, France, ⁵AbbVie, Amadora, Portugal, ⁶AbbVie, North Chicago, IL
Background/Purpose: The long-term safety of anti-tumor necrosis factor (TNF) drugs is particularly important in pediatric patients (pts) who may require prolonged treatment of their inflammatory…
Abstract Number: 2790 • 2013 ACR/ARHP Annual Meeting
The Research In Arthritis In Canadian Children Emphasizing Outcomes (ReACCh Out) Cohort: Are We Achieving Clinically Important Outcomes?
Deborah M. Levy¹, Shirley ML Tse¹, Elizabeth Stringer², Jaime Guzman³, Roberta A. Berard⁴, Karen Watanabe Duffy⁵, Dax Rumsey¹, Mercedes O. Chan³, Rosie Scuccimarri⁶, Adam M. Huber⁷, Lori B. Tucker³, Rae SM Yeung¹, Ciaran M. Duffy⁵, Kiem Oen⁸ and The ReACCh Out Investigators⁹, ¹Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ²Department of Rheumatology, IWK Health Centre, Halifax, NS, Canada, ³Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁴Children's Hospital of Western Ontario, London, ON, Canada, ⁵Rheumatology, Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ⁶McGill University, Montreal, QC, Canada, ⁷Dalhousie University, Halifax, NS, Canada, ⁸Pediatrics, Children's Hospital of Winnipeg and University of Manitoba, Winnipeg, MB, Canada, ⁹The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada
Background/Purpose: Recent data suggests that achievement of inactive disease and early disease remission may result in improved outcomes for patients with juvenile idiopathic arthritis (JIA). …

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].